

WEST

## Freeform Search

Database:

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Term:

11 same 12

Display:

10

Documents in Display Format: -

Starting with Number

20

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

## Search History

DATE: Friday, September 13, 2002 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L4</u>	11 same 12	14	<u>L4</u>
<u>L3</u>	11 and 12	116	<u>L3</u>
<u>L2</u>	cancer	104614	<u>L2</u>
<u>L1</u>	chondroitinase	405	<u>L1</u>

END OF SEARCH HISTORY

**WEST**☐ **Generate Collection** **Print**

L4: Entry 12 of 14

File: USPT

Aug 28, 1984

DOCUMENT-IDENTIFIER: US 4468465 A

TITLE: Diagnosing cancer by observing marker glycosaminoglycans extracted from patient

Detailed Description Text (13):

Viewing the GAGs in cancer (C), it is evident that the major band was depolymerized by both chondroitinase AC and ABC (panels A and D). However, the action of chondroitinase AC (panel A) produced a broad slow moving band; the action of chondroitinase ABC produced a broad band with an intermediate mobility. These results suggest the presence of GAGs with heterogeneous structures, possibly in the form of copolymers. Inspecting the GAGs of the normal prostate (N), both chondroitinase AC and chondroitinase ABC caused a broadening of the intermediate band with a concomitant relative loss of the slow band. In hyperplasia (H) the very broad and diffused band above the slow moving band is lost by the action of chondroitinase AC as well as of chondroitinase ABC. With a loss of the diffused band, there seems to be a broadening of the slow moving band.

Detailed Description Text (14):

The GAGs of panel C were first digested with chondroitinase ABC in an identical manner as those of panel D. After dialysis, the GAGs in the retentate were treated with nitrous acid, which is known to cleave the sulfamide bond in heparan sulfate. In hyperplasia (H) it appears that nitrous acid had no effect upon the chondroitinase ABC-resistant GAGs. In normal (N), the major band that is resistant to chondroitinase ABC was lost by the action of nitrous acid, but with a broadening of the slow band. In cancer (C), the major chondroitinase ABC-resistant band was somewhat diminished.

=> file ca, medline, biosis  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 10:56:36 ON 13 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:56:36 ON 13 SEP 2002

FILE 'BIOSIS' ENTERED AT 10:56:36 ON 13 SEP 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

=> s chondroitinase?  
L1 5298 CHONDROITINASE?

=> s cancer?  
L2 994782 CANCER?

=> s l1 (p) l2  
L3 82 L1 (P) L2

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 41 DUP REM L3 (41 DUPLICATES REMOVED)

Welcome to STN International! Enter x:x

LOGINID:sssptal815mxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr .08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and  
IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and  
ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:56:12 ON 13 SEP 2002

=> file ca, medline, biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CA' ENTERED AT 10:56:36 ON 13 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:56:36 ON 13 SEP 2002

FILE 'BIOSIS' ENTERED AT 10:56:36 ON 13 SEP 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s chondroitinase?

L1 5298 CHONDROITINASE?

=> s cancer?

L2 994782 CANCER?

=> s l1 (p) l2

L3 82 L1 (P) L2

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 41 DUP REM L3 (41 DUPLICATES REMOVED)

=> d 1-41 ab,bib

L4 ANSWER 1 OF 41 CA COPYRIGHT 2002 ACS

AB The invention concerns the use of a compd. antagonist of the ESM-1 protein

for making a medicine for treating cancer. Antagonists may include antibodies, antisense oligonucleotides, and peptide fragments of ESM-1.

AN 136:390975 CA

TI Use of a compound antagonist of the ESM-1 protein for producing a medicine

for treating cancer

IN Lassalle, Philippe; Bechard, David; Tonnel, Andre-Bernard

PA Institut Pasteur de Lille, Fr.; Institut National de la Sante et de la Recherche Medicale (INSERM)

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038178	A1	20020516	WO 2001-FR3475	20011108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

FR 2816214 A1 20020510 FR 2000-14422 20001109  
PRAI FR 2000-14422 A 20001109  
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 1  
AB Exposure to AG73, a synthetic peptide (LQVQLSIR) from the C-terminal  
region of the laminin .alpha.1 chain, induces a malignant phenotype in  
B16F10 melanoma cells. Coinjection of this peptide with the cells  
results  
in an increase of lung tumors and also the formation of liver tumors in  
.apprx.50% of the mice (W. H. Kim et al., Int. J. **Cancer**, 77:  
632-639, 1998). Here we have characterized the cell surface receptor and  
its functional groups on B16F10 cells. Peptide affinity chromatog.  
identified a cell surface protein eluting with 1 M NaCl, which ran in SDS  
gels as a broad band of Mr .apprx.150,000-200,000. Digestion with  
heparitinase and **chondroitinase** produced a core protein of lower  
mol. wt. (Mr .apprx.90,000). Involvement of the glycosaminoglycan (GAG)  
side chains was demonstrated by inhibition of cell binding to the peptide  
by heparin, heparan sulfate, and chondroitin sulfate B, but not by  
chondroitin sulfates A or C, or hyaluronic acid. The IC50 for heparin  
was  
the lowest, followed by heparan sulfate, then chondroitin sulfate B,  
suggesting that the overall sulfation of the GAG side chain is crit.  
This  
was confirmed by inhibition of attachment with chem. modified heparin and  
heparan sulfate, which also showed that N or O linkages were not  
important  
for function. Using sized heparin fragments to inhibit cell binding to  
the peptide demonstrated that 16-mer is the min. length required. B16F10  
cells form a network when grown on Matrigel, and this is prevented by  
addn. of the AG73 peptide. The GAGs alone did not affect network  
formation, but heparin, heparan sulfate, and chondroitin sulfate B  
reversed the inhibitory effect of the peptide, whereas other GAGs were  
inactive. Furthermore, removal of cell surface GAGs inhibited cell  
attachment to the peptide. Cells treated with glycosidases and  
coinjected  
with the peptide formed liver tumors equal to the control group receiving  
no peptide, suggesting that the GAGs play an early role in  
peptide-mediated tumor metastasis. These data indicate that the B16F10  
cell receptor for a laminin metastasis-promoting sequence is a heparan  
sulfate/chondroitin sulfate-contg. proteoglycan, and these GAG side  
chains  
are functionally important in the cell-peptide interaction.  
AN 137:167275 CA  
TI The B16F10 cell receptor for a metastasis-promoting site on laminin-1 is  
a  
heparan sulfate/chondroitin sulfate-containing proteoglycan  
AU Engbring, Jean A.; Hoffman, Matthew P.; Karmand, Arezo J.; Kleinman,  
Hynda  
K.  
CS Craniofacial Developmental Biology and Regeneration Branch, National  
Institute of Dental and Craniofacial Research, NIH, Bethesda, MD,  
20892-4370, USA  
SO Cancer Research (2002), 62(12), 3549-3554  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research

DT Journal  
LA English  
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 41 MEDLINE

AB Glycosaminoglycans in normal and **cancerous** human laryngeal cartilage were isolated and characterized by means of enzyme susceptibility and high performance liquid chromatography. The known mammalian glycosaminoglycans were identified in all samples but their content and composition varied between normal and malignant samples. Chondroitin/dermatan sulphate was the major glycosaminoglycan in all cases, but its relative proportion was decreased in malignant samples.

Its

sulphation pattern showed that in normal samples it was sulphated mainly at the C6 position of galactosamine, whereas in malignant samples it was sulphated mainly at C4. Dermatan sulphate, expressed as a result of the different digestion of samples with **chondroitinases**, was present in very small amounts in normal samples (2.7% of total sulphated glycosaminoglycans) but increased in proportion up to 27.7% in malignant samples. The content of oversulphated chondroitin/dermatan was increased twofold in malignant samples. The content of heparan sulphate was increased almost fivefold in malignant samples as compared to normal

ones.

The content of hyaluronan was increased in malignant samples 3.5-fold, amounting to up to 11.4% of total glycosaminoglycans. These dramatic changes in the content and composition of glycosaminoglycans seemed to be characteristic of the tumour and independent of its status.

AN 2002290524 IN-PROCESS

DN 22026172 PubMed ID: 12030585

TI Alterations in the content and composition of glycosaminoglycans in human laryngeal carcinoma.

AU Papadas Th A; Stylianou M; Mastronikolis N S; Papageorgakopoulou N; Skandalis S; Goumas P; Theocharis D A; Vynios D H

CS Department of Otolaryngology, University Hospital, University of Patras, Greece.

SO ACTA OTO-LARYNGOLOGICA, (2002 Apr) 122 (3) 330-7.  
Journal code: 0370354. ISSN: 0001-6489.

CY Norway

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS IN-PROCESS; NONINDEXED; Priority Journals

ED Entered STN: 20020528

Last Updated on STN: 20020528

L4 ANSWER 4 OF 41 CA COPYRIGHT 2002 ACS

AB A highly purified and specific glycosaminoglycan degrading enzyme, **chondroitinase** AC, and to a lesser extent, **chondroitinase** B, can be used in the treatment of metastatic **cancers** and in other disorders characterized by angiogenesis. The enzymic removal of chondroitin sulfates A and C, and to a lesser extent, chondroitin sulfate B, from cell surfaces directly decreases the ability of tumor cells to invade blood vessels and thus prevents the formation of metastatic, or secondary tumors; inhibits tumor cell growth; and decreases angiogenesis by inhibiting both endothelial cell proliferation and capillary formation.

Decreasing the formation of new blood vessels into the tumor in turn decreases the potential for tumor growth, and further decreases the ability of tumor cells to invade the bloodstream. These effects are opposite to the pro-metastatic effects of tumor-secreted heparanase.

AN 134:361354 CA  
 TI Attenuation of tumor growth, metastasis and angiogenesis  
 IN Denholm, Elizabeth M.; Lin, Yong-qing; Silver, Paul J.  
 PA Ibex Technologies, Inc., USA  
 SO PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001035977	A2	20010525	WO 2000-US31663	20001117
	WO 2001035977	A3	20020117		
	WO 2001035977	C2	20020725		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1231935	A2	20020821	EP 2000-978781	20001117
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 1999-165957P	P	19991117		
	WO 2000-US31663	W	20001117		

L4 ANSWER 5 OF 41 CA COPYRIGHT 2002 ACS

DUPLICATE 2

AB A sensitive and accurate quant. assay for the measurement of minor amts. of chondroitin/dermatan sulfate and heparan sulfate that does not require specific app. or reagents is described. The assay involves labeling of chondroitin sulfate A following reaction of carboxyl groups with biotin hydrazide in the presence of carbodiimide. ELISA plate wells were coated with glutaraldehyde and then spermine was coupled to it via a Schiff's base bond. In such activated wells, the biotinylated mols. were readily bound and detected after the interaction with avidin-peroxidase conjugates and the subsequent enzymic assay. Chondroitin/dermatan sulfate and heparan sulfate competed this interaction in a linear manner. Disaccharides derived from chondroitin sulfate A did not act as competitors, while heparan sulfate disaccharides showed significant competition. From the competition, before and after digestion with either

**chondroitinase** ABC or heparitinases, the amts. of chondroitin sulfate and heparan sulfate in a sample could be calcd. The assay was applied for the detn. of sulfated glycosaminoglycans in normal and **cancerous** human laryngeal cartilage samples. By using this procedure, the accurate detn., esp., of heparan sulfate in a mixt. of glycosaminoglycans was achieved, which otherwise would require the use of very expensive technol.

AN 136:116438 CA

TI A solid phase assay for the determination of heparan sulfate and its application to normal and cancerous human cartilage samples

AU Vynios, D. H.; Papadas, Th. A.; Faraos, A.; Mastronikolis, N. S.; Goumas, P.; Tsiganos, C. P.

CS Laboratory of Biochemistry, Department of Chemistry, University Hospital, University of Patras, Patras, 261 10, Greece

SO Journal of Immunoassay & Immunochemistry (2001), 22(4), 337-351

CODEN: JIIOAZ; ISSN: 1532-1819  
PB Marcel Dekker, Inc.  
DT Journal  
LA English  
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 41 MEDLINE DUPLICATE 3  
AB The chondroitin sulfate excreted in the urine of 10 patients with **cancer** of the head and neck and 27 healthy subjects was analyzed. The disaccharide products formed from chondroitin sulfate excreted by these 10 patients by action of **chondroitinase** ABC show a significant ( $P < 0.0001$ ) relative increase of nonsulfated disaccharide ( $35.6\% \pm 5.7\%$ ) when compared with the nonsulfated disaccharide ( $10.0\% \pm 0.9\%$ ) present in the chondroitin sulfate of 27 healthy subjects. In 6 patients the structure of the excreted compound was analyzed up to 4 months after surgery. After removal of the **cancer**, the percent amounts of the nonsulfated disaccharide tend to approach the values found for the chondroitin sulfate of healthy subjects. A significant ( $P < 0.0001$ ) change in the ratio of urinary chondroitin sulfate and heparan sulfate and a decrease in the electrophoretic migration of chondroitin sulfate were also observed. All of the patients with head and neck **cancer** analyzed so far have shown this structural anomaly of urinary chondroitin sulfate. This assay may be useful in the diagnosis

and follow-up of **cancer** therapy.

AN 2000096790 MEDLINE  
DN 20096790 PubMed ID: 10629497  
TI Patients with head and neck tumors excrete a chondroitin sulfate with a low degree of sulfation: a new tool for diagnosis and follow-up of cancer therapy.  
AU Martins J R; Gadelha M E; Fonseca S M; Sampaio L O; De L Pontes P A; Dietrich C P; Nader H B  
CS Departamento de Bioquimica-Biologia Molecular, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Brazil.  
SO OTOLARYNGOLOGY - HEAD AND NECK SURGERY, (2000 Jan) 122 (1) 115-8.  
Journal code: 8508176. ISSN: 0194-5998.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200002  
ED Entered STN: 20000209  
Last Updated on STN: 20000209  
Entered Medline: 20000203

L4 ANSWER 7 OF 41 CA COPYRIGHT 2002 ACS  
AB A novel midkine-binding protein is purifd. from a brain ext. prepd. from a  
13.5-day wild type ICR mouse embryo by immunopptn. using an antibody to midkine. The protein is localized on the cell surface membrane and is able to bind to midkine and heparin-binding midkine. The protein is insensitive to heparinase I, apprx. III, keratanase, or **chondroitinase**. Antibodies to receptor-type phosphotyrosine phosphatase .xi. do not recognize the protein. This protein is useful in screening candidate compds. for drugs such as remedies for **cancer**. Methods for cloning the protein-encoding cDNA sequence are also claimed  
(not sequences given).

AN 131:125924 CA  
 TI Novel midkine-binding protein from ICR mice  
 IN Muramatsu, Takashi; Kadomatsu, Kenji; Ikematsu, Shinya; Sakuma, Sadatoshi  
 PA Meiji Milk Products Co., Ltd., Japan  
 SO PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938971	A1	19990805	WO 1999-JP423	19990202
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9920765	A1	19990816	AU 1999-20765	19990202
PRAI	JP 1998-35518		19980202		
	WO 1999-JP423		19990202		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 4  
 AB Previous in vitro studies have shown CD44 isoforms contg. the alternatively spliced exon v3 (CD44v3) to be modified with heparan sulfate  
 (HS) and to bind HS-binding basic fibroblast growth factor (bFGF). Here, we demonstrate that exogenously added bFGF is also bound in vivo by CD44v3-pos. keratinocytes in normal skin and by tumor cells in basal cell carcinoma and squamous cell carcinoma (SCC), two skin **cancers** of keratinocyte origin. BFGF binding and CD44v3 expression were colocalized in cultured human normal keratinocytes (HNK) and on the SCC cell line A431. By contrast, benign or malignant tumors of melanocyte origin failed to express CD44v3 and bound no bFGF. The bFGF binding to normal or transformed keratinocytes in vivo and in vitro was dependent on HS modification, as it was completely eliminated by pretreatment with heparitinase or by blocking with free heparin, whereas **chondroitinase** had no effect. In addn., specific removal of CD44v3 by antibody-induced shedding also diminished bFGF binding to keratinocytes. Furthermore, bFGF stimulated the proliferation of CD44v3-pos. HNK and A431 in a dose-dependent fashion. This bFGF effect was again completely abolished by heparitinase or free heparin, but not by **chondroitinase**. In aggregate, these results suggest that a function of HS-modified CD44 isoforms such as CD44v3 in skin is to present

the HS-binding growth factor bFGF, thereby stimulating the proliferation of normal or transformed keratinocytes.

AN 132:306445 CA  
 TI Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers  
 AU Grimme, H. U.; Termeer, C. C.; Bennett, K. L.; Weiss, J. M.; Schopf, E.; Aruffo, A.; Simon, J. C.  
 CS Department of Dermatology, University of Freiburg, Freiburg, D-79104, Germany  
 SO British Journal of Dermatology (1999), 141(5), 824-832  
 CODEN: BJDEAZ; ISSN: 0007-0963  
 PB Blackwell Science Ltd.  
 DT Journal

LA English

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 41 CA COPYRIGHT 2002 ACS

AB A method for the treatment of cancer is disclosed which is capable of directing supralethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer. The present invention involves a multi-step therapy process and includes a class of novel chem. agents. In accordance

with the invention, it was discovered that sol. precipitable materials can

be made to accumulate as non-digestible ppts. in targeted cells as a result of enzyme action within the targeted cells. Accumulation is achieved by administering to the living host a sol. binary reagent made

by attaching a targeting agent to a novel chem. agent which is a sol. precipitable material. The binary reagent binds to antigenic receptors

on targeted cells which endocytose binary reagent and transport it into the lysosomes where enzymes detach the sol. precipitable material from the targeting agent, causing it to ppt., accumulate, and be retained in the cells. Increasing amts. of ppt. can be made to accumulate in cells by continuing the administration of the binary reagent. The accumulated

ppt. is relocated to the extra-cellular fluid by selectively killing a fraction

of cancer cells. Now relocated in the extra-cellular fluid of the cancer,

the ppt. is used as a "platform" from which to generate Hot-Spots. A bispecific reagent with a non-mammalian enzyme moiety is made to bind to the ppt. A sol. radioactive material is administered which is converted by the enzyme moiety of the bound bispecific reagent into a new form

which is retained adjacent to the ppt. for an extended period of time, thereby generating Hot-Spots which non-selectively kill all cells adjacent to the ppt. in the extra-cellular fluid of the cancer.

AN 129:133126 CA

TI A method and composition for cancer treatment by enzymic conversion of soluble radioactive toxic agents

IN Rose, Samuel

PA Rose, Samuel, USA

SO PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 9830247	A1	19980716	WO 1998-US511	19980113
	W: AU, CA, JP, KR, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	US 6080383	A	20000627	US 1997-782219	19970113
	AU 9859131	A1	19980803	AU 1998-59131	19980113
	EP 1047456	A1	20001102	EP 1998-902485	19980113
	R: CH, DE, FR, GB, IT, LI, NL, SE				
	JP 2001524941	T2	20011204	JP 1998-531191	19980113
	US 2002022003	A1	20020221	US 1999-314422	19990518
PRAI	US 1997-782219	A	19970113		

L4 ANSWER 10 OF 41 CA COPYRIGHT 2002 ACS

AB 1st ligands and 2nd ligands in a sample are detd. by contacting the sample

with a solid phase on which both of 1st receptors and 2nd receptor-1st ligand-1st receptor complexes are immobilized, and detecting formation of the complexes between the 1st receptors and the 1st ligands and that between the 2nd receptors and the 2nd ligands, e.g. using labeled 1st receptors and labeled 2nd receptors, resp. The kits comprise the solid phase, the labeled 1st receptors, and the labeled 2nd receptors. Detn.

of

keratan sulfate (I) and hyaluronic acid (II) by the method is useful for primary screening of, osteoarthritis, rheumatoid arthritis, corneal disease, **cancer**, Morquio's syndrome, Hurler's syndrome, etc. Simultaneous detn. of I and II using a multiwell plate in which each well was successively treated with anti-keratan sulfate antibodies and **chondroitinase** ABC-hydrolyzed bovine nose cartilage-derived proteoglycans, biotinylated anti-keratan sulfate antibodies, and biotinylated hyaluronic acid-binding proteins.

AN 129:51706 CA

TI Method, solid phase, and kits for simultaneous determination of two kinds of ligands

IN Okamura, Kazuo; Yoshida, Hiroko

PA Seikagaku Kogyo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10153600	A2	19980609	JP 1996-311738	19961122

L4 ANSWER 11 OF 41 CA COPYRIGHT 2002 ACS

DUPLICATE 5

AB The authors previously demonstrated that lactoferrin increases breast cell

sensitivity to natural killer cell cytotoxicity whereas hematopoietic cells are unaffected by lactoferrin. It has been described that lactoferrin binds to various glycosaminoglycans. Compared to hematopoietic cells, breast **cancer** cells and particularly the breast cell line MDA-MB-231, possess a high level of proteoglycans. Scatchard anal. of 125I-lactoferrin binding to MDA-MB-231 cells revealed the presence of two classes of binding sites: a low affinity site with a Kd of about 700 nM and 3.9 .times. 10<sup>6</sup> sites and a higher affinity class with a Kd of 45 nM and 2.9 .times. 10<sup>5</sup> sites per cell. To investigate

the

potential regulation of lactoferrin activity by proteoglycans expressed

on

the MDA-MB-231 cells, the authors treated these cells with glycosaminoglycan-degrading enzymes or sodium chlorate, a metabolic inhibitor of proteoglycan sulfation. The authors showed that **chondroitinase** treatment has no effect, while heparinase or chlorate treatment significantly reduces both the binding of lactoferrin to cell surface sulfated mols. such as heparan sulfate proteoglycans (HSPG) and the affinity of lactoferrin for the higher affinity binding sites. The modulation of the lactoferrin binding was correlated with a decrease in lactoferrin activities on both MDA-MB-231 cell sensitization to lysis and proliferation. Taken together, these results suggest that the presence of adequately sulfated mols., in particular HSPG, is

important for lactoferrin interaction and activity on the breast  
**cancer** cells MDA-MB-231.

AN 130:108457 CA

TI Role of heparan sulfate proteoglycans in the regulation of human  
lactoferrin binding and activity in the MDA-MB-231 breast cancer cell  
line

AU Damiens, Eve; El Yazidi, Ikram; Mazurier, Joel; Ellass-Rochard, Elisabeth;  
Duthille, Isabelle; Spik, Genevieve; Boilly-Marer, Yolande

CS Lab. Chimie Biologique, Univ. Sciences Technologies Lille, Villeneuve  
d'Ascq, F-59655, Fr.

SO European Journal of Cell Biology (1998), 77(4), 344-351  
CODEN: EJCBDN; ISSN: 0171-9335

PB Gustav Fischer Verlag

DT Journal

LA English

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 6

AB Gene therapy may be an important adjuvant for treating **cancer** in  
the pleural space. The initial results of retroviral gene transfer to  
**cancer** cells in malignant pleural effusions revealed that  
transduction was markedly inhibited, and studies to characterize the  
inhibitory factor(s) were performed. The inhibition was contained within  
the sol., rather than cellular, components of the effusions and was  
demonstrated with amphotropic gibbon ape leukemia virus, and vesicular  
stomatitis virus-glycoprotein pseudotyped retroviral vectors. After  
excluding complement proteins, a series of studies identified chondroitin  
sulfates (CSs) as the inhibitory substances. First, treatment of the  
effusions with mammalian hyaluronidase or **chondroitinases**, but  
not Streptomyces hyaluronidase, abolished the inhibitory activity.  
Second, addn. of exogenous CS glycosaminoglycans mimicked the inhibition  
obsd. with pleural effusions. Third, immunoassays and biochem. analyses  
of malignant pleural effusion specimens revealed CS in relevant concns.  
within pleural fluid. Fourth, proteoglycans/glycosaminoglycans isolated  
from the effusions inhibited retroviral gene transfer. Analyses of the  
mechanism of inhibition indicate that the chondroitin sulfates interact  
with vector in soln. rather than at the target cell surface. These  
results suggest that drainage of the malignant pleural effusion, and  
perhaps enzymic pretreatment of the pleural cavity, will be necessary for  
efficient retroviral vector mediated gene delivery to pleural metastases.

AN 127:366 CA

TI Retroviral gene transfer is inhibited by chondroitin sulfate  
proteoglycans/glycosaminoglycans in malignant pleural effusions

AU Batra, Raj K.; Olsen, John C.; Hoganson, Diana K.; Caterson, Bruce;  
Boucher, Richard C.

CS Div. Pulmonary Diseases, Dep. Med., Univ. North Carolina, Chapel Hill,  
NC,

27599-7248, USA

SO Journal of Biological Chemistry (1997), 272(18), 11736-11743  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

L4 ANSWER 13 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 7

AB Heparin/heparan sulfate interacting protein (HIP) is a recently  
identified

protein expressed by many normal epithelia and epithelial cell lines. In  
the present study, the authors examd. expression and potential functions

of this protein in a series of human breast **cancer** cells and in sections of normal and malignant human breast tissue. Four of the five breast **cancer** cell lines studied (MCF-7, T-47D, MDA-MB-468, and BT-549 ) expressed HIP protein and mRNA at similar levels. In contrast, MDA-MB-231 cells failed to display reactivity with HIP-specific probes in any assay. Cell aggregation assays and cell surface antibody binding studies demonstrated that HIP was expressed on the cell surface.

However,

HIP expression did not correlate with the no. of cell surface [3H]heparin (HP) binding sites. The KDapps for cell surface HP binding sites were similar in all breast **cancer** cell lines studied and ranged from 112 to 298 nM. In contrast, cell surface HP binding capacity varied greatly, ranging from 2.3 .times. 10<sup>5</sup> (MDA-MB-231 and MDA-MB-468) to 99 .times. 10<sup>5</sup> sites/cell (BT-549). All cell lines tested displayed the ability to bind to a heparan sulfate (HS)-binding synthetic peptide motif of HIP in a HP-inhibitable fashion. Binding to this motif was not inhibited by other glycosaminoglycans including hyaluronic acid, chondroitin sulfates, or keratan sulfate. Furthermore, cell binding to HIP peptide was almost completely lost when intact cells were predigested with heparinases but not **chondroitinases**. Cell surface HS from breast **cancer** cells as well as normal human breast epithelia bound to HIP peptide in a HP-inhibitable fashion, demonstrating the ability of these cell surface components to directly interact. HIP was detected in both normal breast epithelia and breast tumors in situ. It

is

suggested that HIP mediates aspects of HS-dependent interactions of both normal and malignant breast epithelia with other cells and extracellular matrix components.

AN 128:46572 CA

TI Heparin/heparan sulfate interacting protein expression and functions in human breast cancer cells and normal breast epithelia

AU Jacobs, Andrew L.; Julian, Joanne; Sahin, Aysegula A.; Carson, Daniel D.

CS Departments of Biochemistry and Molecular Biology, The University of Texas

M. D. Anderson Cancer Center, Houston, TX, 77030, USA

SO Cancer Research (1997), 57(22), 5148-5154

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

L4 ANSWER 14 OF 41 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB Immunohistochemical expression of standard and v6 isoforms of CD44 was performed on specimens from three groups of prostate **cancer** patients: Group I, primary prostate **cancers** (N=31); Group II, lymph node metastases (N=18); and Group III, bone metastases (N=15). In addition, serum from all Group I patients was analyzed for soluble CD44 expression. Benign glands exhibited strong CD44s and CD44v6 expression in basal cells. Weak basolateral staining was identified in superficial luminal cells. Malignant glands and metastatic tumors revealed diminished or absent expression of both CD44s and CD44v6 with a heterogeneous pattern. Pretreatment with **chondroitinase** did not significantly alter CD44 expression. Soluble CD44 was present in all serum samples, however, expression was variable. There was no statistically significant correlation between immunohistochemical CD44 expression, soluble CD44 expression, and clinical progression.

AN 1997:261136 BIOSIS

DN PREV199799567739

TI Immunohistochemical and soluble expression of CD44 in primary and metastatic human prostate cancers.

AU Griebbling, Tomas L.; Palechek, Patricia L.; Cohen, Michael B. (1)  
CS (1) Dep. Pathol., Univ. Iowa, 200 Hawkins Drive, 5216 RCP, Iowa City, IA  
52242 USA  
SO International Journal of Oncology, (1997) Vol. 10, No. 4, pp. 697-702.  
ISSN: 1019-6439.  
DT Article  
LA English

L4 ANSWER 15 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 8  
AB Thrombospondin is an adhesive glycoprotein that promotes breast  
**cancer** cell adhesion to human vascular endothelial cells. In this  
study, we have identified the mol. domains of thrombospondin that mediate  
its binding to specific receptors on the human breast adenocarcinoma cell  
line, MDA-MB-231. Two recombinant fragments from the amino-terminus  
(TSPN18 and TSPN28), and the fusion proteins of the type 1 and type 2  
repeats of human thrombospondin, inhibited binding of radiolabeled  
thrombospondin to MDA-MB-231 cells in suspension by 40-60% at 50 .mu.g/mL  
whereas the type 3 repeat, carboxy-terminus and unfused  
glutathione-S-transferase as well as the synthetic peptide  
Gly-Arg-Gly-Asp-Ser (500 .mu.g/mL) had little or no effect. Heparin are  
various glycosaminoglycans as heparan sulfate, chondroitin sulfates A, B  
or C, and fuccoidan inhibited thrombospondin binding to MDA-MB-231 cells

by  
more than 60% whereas dextran sulfate had only little effect. Treatment  
of cells with heparitinase, **chondroitinase** ABC, and  
hyaluronidase, but not with neuraminidase, induced 30-50% inhibition of  
thrombospondin binding suggesting the participation of both heparan  
sulfate and chondroitin sulfate cell surface-assocd. mols. Inhibition of  
proteoglycan sulfation by chlorate or inhibition of glycosaminoglycan  
chain formation by two .beta.-D-xylosides also led to a substantial  
inhibition of thrombospondin binding. Our results indicate that several  
domains within the thrombospondin mol., namely the amino-terminus, type 1  
and type 2 repeats, participate in its binding to specific receptors  
bearing sulfated glycosaminoglycans on MDA-MB-231 cells. Biol. assays  
have indicated that, in addn. to these domains, the peptide  
Gly-Arg-Gly-Asp-Ser inhibited MDA-MB-231 cell attachment to

thrombospondin  
suggesting that the last type 3 repeat of the mol. may also contribute to  
its cell adhesive activity.

AN 125:272226 CA  
TI Heparin-binding domain, type 1 and type 2 repeats of thrombospondin  
mediate its interaction with human breast cancer cells  
AU Incardona, Francesca; Lawler, Jack; Cataldo, Didier; Panet, Amos;  
Legrand,

Yves; Foidart, Jean Michel; Legrand, Chantal  
CS Hop. Saint Louis, Paris, 75010, Fr.  
SO Journal of Cellular Biochemistry (1996), 62(4), 431-442  
CODEN: JCEBD5; ISSN: 0730-2312  
PB Wiley-Liss  
DT Journal  
LA English

L4 ANSWER 16 OF 41 CA COPYRIGHT 2002 ACS  
AB A review with 17 refs. Zymog. for detecting **chondroitinase** and  
hyaluronidase was developed using chondroitin sulfate-immobilized  
acrylamide gel. For human serum two band were detected in hyaluronic  
acid  
zymog., but one of them was neg. in chondroitin sulfate zymog.  
Chondroitin sulfate zymog. of ext. from human womb **cancer** cells  
revealed a new hyaluronidase of 94 kDa which was specific for hyaluronic

acid. Antibody to the enzyme makes possible to clone a responsible gene and to show a dynamic mechanism for degrading glycosaminoglycan chains.

AN 125:28705 CA  
 TI Glycosaminoglycan-degrading enzymes as revealed by zymography  
 AU Yamagata, Tatsuya  
 CS Fac. Biosci. Biotechnol., Tokyo Inst. Technol., Yokohama, 226, Japan  
 SO Igaku no Ayumi (1996), 177(1), 36-41  
 CODEN: IGAYAY; ISSN: 0039-2359  
 PB Ishiyaku  
 DT Journal; General Review  
 LA Japanese

L4 ANSWER 17 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 9  
 AB The purpose of this study was to det. the biochem. and mol. characteristics of mucin synthesized by cystic fibrosis cells (CFPAC-1),

a  
 pancreatic **cancer** cell line derived from a patient with cystic fibrosis, and pancreatic **cancer** (SW-1990) cell lines. High mol. wt. glycoproteins (HMG) were quantified by [3H]-glucosamine labeling and chromatog. on Sepharose CL-4B. Mucin gene expression was detd. by using cDNA probes for 2 distinct intestinal mucins (MUC2 and MUC3) and one stomach mucin (MUC1). The specific mucin core epitopes were confirmed by immunoblots using antibodies that recognize T, Tn, sialosyl Tn, MUC1, and MUC3. The results of these expts. demonstrate that CFPAC-1 cells contained 1.25 fold and 1.4 fold more HMG in the membrane and cytosolic fractions, and secreted 4-fold more HMG into the medium compared to SW-1990 cells. The HMG of SW-1990 was mucinous in nature and not proteoglycans, as it was not susceptible to hyaluronidase, heparinase and **chondroitinase** ABC. The HMG of CFPAC-1 was also predominantly (80%) mucinous but with small amts. of proteoglycans. The mRNA and immunoblot anal. suggest that these CFPAC-1 and SW-1990 cells predominantly express MUC1 apomucin, small amts. of MUC2 apomucin, and no MUC3. Pulse chase labeling and immunopptn. of MUC1 type mucin using the 139H2 monoclonal antibody demonstrated that different sizes of mucin gene product were present in both cell lines, corresponding to the known

length  
 polymorphism of this mucin. Both T and Tn antigens were significantly higher in CFPAC-1 and SW-1990 cells as compared to sialosyl Tn antigen. These findings were assocd. with the increased activities of polypeptidyl N-acetylgalactosaminyltransferase and .beta.1,3-galactosyltransferase. These investigations demonstrate for the first time that cystic fibrosis cells (CFPAC-1) secrete and synthesize high amts. of mucin which is assocd. with high levels of MUC1 mRNA, low levels of MUC2 mRNA and nondetectable MUC3 mRNA.

AN 122:262936 CA  
 TI Cystic fibrosis and pancreatic cancer cells synthesize and secrete MUC1 type mucin gene product  
 AU Dahiya, Rajvir; Kwak, Kyu-Shik; Ho, Samuel B.; Yoon, Wan-Hee; Kim, Young S.  
 CS Dep. Med., Univ. California, San Francisco, CA, USA  
 SO Biochemistry and Molecular Biology International (1995), 35(2), 351-62  
 CODEN: BMBIES; ISSN: 1039-9712  
 PB Academic  
 DT Journal  
 LA English

L4 ANSWER 18 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 10  
 AB The authors investigated changes in the glycosaminoglycans (GAGs) during progression of a human gingival carcinoma xenograft line, GK-1, in nude mice. The GAGs extd. from **cancers** 3, 5, 7, 10 and 15 wk after

transplantation consisted of hyaluronic acid (HA), chondroitin sulfate (CS) and heparan sulfate (HS) as major components, and dermatan sulfate (DS) as a trace component for all **cancers**. HPLC anal. revealed that the HA content per defatted tissue dry wt. increased in the **cancers** 5 wk after transplantation compared to those of 3 wk, while CS for **cancers** at 10 wk decreased compared with 7 wk. However, HS showed no significant change. Both the CS and DS contained primarily 4-sulfated disaccharide units. Immunohistochem. staining with antibody 2-B-6 for the PGs having .DELTA.Di-4S produced by **chondroitinase** ABC digestion showed that CS is located in the tissue surrounding the **cancer** nests and mass. These results indicate that the location of accumulation of CS, which primarily

contains

4-sulfated disaccharide units, plays an important role in **cancer** progression.

AN 125:111600 CA

TI Changes in glycosaminoglycan characteristics during progression of a human

gingival carcinoma xenograft line in nude mice

AU Ida, Masayasu; Kamada, Aiko

CS Department Biochemistry, Osaka Dental University, Osaka, 540, Japan

SO Journal of Osaka Dental University (1995), 29(2), 39-50

CODEN: JODUA2; ISSN: 0475-2058

PB Osaka Dental University

DT Journal

LA English

L4 ANSWER 19 OF 41 CA COPYRIGHT 2002 ACS

DUPLICATE 11

AB Previous studies have suggested that mucin gene expression is tissue-specific; however, the relationship between unique mucin gene products and the biochem. properties of mucins is unknown. The purpose

of

this study was to det. the biochem. and mol. characteristics of mucin synthesized by adenocarcinoma cell lines derived from breast (ZR-75-1), stomach (MGC-803), pancreas (Capan-2), and lung (Chago K-1). Mucin was quantitated by [3H]glucosamine labeling and Sepharose CL-4B chromatog. The mucinous nature of the labeled high mol. wt. glycoproteins (HMG) was verified by alk. borohydride treatment, cesium chloride d. gradient ultracentrifugation, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Specific mucin gene expression was detd. using cDNA probes for 2 distinct intestinal mucins (MUC-2 and MUC-3) and one breast **cancer** mucin (MUC-1). Specific core mucin proteins were confirmed by immunoblots using antibodies that recognize MUC-1, MUC-2, and MUC-3 core peptides. These expts. demonstrate that all cell lines contained

HMG

in the medium, cytosol, and membrane fractions. The HMG was mucinous in breast, pancreatic, and lung cell lines. In contrast, most of the HMG secreted by the gastric cell line was proteoglycan-like, due to its susceptibility to hyaluronidase, heparinase, and **chondroitinase** avidin-biotin complex. Ion-exchange (DEAE-Sephacel) chromatog. of [3H]glucosamine-labeled HMG demonstrated that the acidic or basic nature of the mucin was different in all **cancer** cell lines tested. Despite these differences, mRNA and immunoblot anal. suggest that all

cell

lines predominantly express MUC-1 apomucin, small amts. of MUC-2

apomucin,

and no MUC-3. Immunopptn. of MUC-1-type mucin using the 139H2 monoclonal antibody demonstrated that different sizes of mucin peptides were present in all cell lines, corresponding to the known length polymorphism of this mucin. The amt. and nature of carbohydrate epitopes were analyzed by

immunoblots using anti-T (peanut lectin), anti-Tn (91S8 monoclonal antibody), and antisialosyl Tn (JT10e monoclonal antibody). T and Tn antigens were significantly higher in breast and pancreatic cells as compared with lung and gastric cell lines. These findings correlated with increased activities of polypeptidyl N-acetylgalactosaminyl transferase and .beta.-1,3-galactosyltransferase. These expts. demonstrate that in contrast to colon **cancer** cell lines described previously, which expressed high levels of MUC-2 and MUC-3 mRNA, the mucin synthesized by breast, pancreatic, gastric, and lung cell lines is assocd. with high levels of MUC-1 mRNA, low levels of MUC-2 mRNA, and an absence of MUC-3 mRNA. However, the mucin in these cells differs greatly in amt., distribution, and biochem. and immunol. properties.

AN 119:46467 CA  
 TI Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene  
 AU Dahiya, Rajvir; Kwak, Kyu Shik; Byrd, James C.; Ho, Samuel; Yoon, Wan Hee; Kim, Young S.  
 CS Dep. Med., Univ. California, San Francisco, CA, USA  
 SO Cancer Res. (1993), 53(6), 1437-43  
 CODEN: CNREA8; ISSN: 0008-5472  
 DT Journal  
 LA English

L4 ANSWER 20 OF 41 MEDLINE DUPLICATE 12  
 AB BACKGROUND: Chondroitin sulfate is significantly increased in tumors (10 to 100 times) when compared to the amounts present in normal adjacent tissues. To investigate if the changes in concentration of chondroitin sulfate could be reflected in the urine of **cancer** patients we have analyzed the chondroitin sulfate excreted by 44 patients with different types of tumors, 50 normal individuals and 15 patients with unrelated diseases. EXPERIMENTAL DESIGN: The identification and structural analyses of the sulfated glycosaminoglycans were made by electrophoresis and degradation with specific enzymes (**chondroitinases** AC and ABC), identification/quantitation of their disaccharide products by chromatography (paper and HPLC) and chemical determinations. RESULTS: The disaccharide products formed from chondroitin sulfate of the 44 **cancer** patients by action of **chondroitinase** ABC show a substantial relative increase of non sulfated disaccharide (32.1% +/- 11.5) with a relative decrease of 6-sulfated disaccharide (28.9% +/- 11.5) and 4-sulfated disaccharide (39.0% +/- 13.5) when compared to the chondroitin sulfate of normal subjects (9.1% +/- 2.2, 40.6% +/- 4.5 and 50.2% +/- 4.5, respectively) or from patients with unrelated diseases. There is a direct correlation between the non sulfated disaccharide content and the stage of malignancy of the **cancer** patients. A significant change of the ratio of chondroitin sulfate and heparan sulfate and a decrease in the electrophoretic migration of chondroitin sulfate were also observed in **cancer** patients. CONCLUSIONS: All the **cancer** patients analyzed so far have shown the structural anomaly of the urinary chondroitin sulfate and this may be useful in the diagnosis and follow up of **cancer** therapy.

AN 93240809 MEDLINE  
 DN 93240809 PubMed ID: 8479152  
 TI Anomalous structure of urinary chondroitin sulfate from cancer patients.  
 A

potential new marker for diagnosis of neoplasias.

AU Dietrich C P; Martins J R; Sampaio L O; Nader H B  
 CS Departamento de Bioquimica, Escola Paulista de Medicina, Sao Paulo, Brazil.  
 SO LABORATORY INVESTIGATION, (1993 Apr) 68 (4) 439-45.  
 Journal code: 0376617. ISSN: 0023-6837.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199305  
 ED Entered STN: 19930611  
 Last Updated on STN: 19930611  
 Entered Medline: 19930525

L4 ANSWER 21 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 13  
 AB The synthesis and secretion of mucin-like high-mol. glycoprotein was studied in 2 human colon **cancer** cell lines that spontaneously differentiate in culture (Caco-2 and T84) and in 2 cell lines that do not spontaneously differentiate (LS174T and HT29). Mucin, quantitated by 3H-glucosamine labeling and chromatog. on Sepharose CL-4B, was produced by all 4 cell lines. The mucinous nature of the labeled high-mol. glycoprotein was verified by enzymic degradn. treatments (heparinase, hyaluronidase, **chondroitinase** ABC, and N-glycanase), alk.-borohydride treatment, inhibition of labeling by the glycosylation inhibitor benzyl-.alpha.-GalNAc, and by CsCl-d.-gradient centrifugation. In all 4 cell lines, an inverse correlation of mucin synthesis with cell d. was demonstrated. In Caco-2 cells, the spontaneous post-confluent enterocytic differentiation with increased brush-border enzyme expression was assocd. with a decrease in mucin synthesis and in the activities of polypeptidyl GalNAc transferase and .beta.1,3-galactosyltransferase activity. Using cDNA probes for 2 distinct human intestinal mucins (MUC2 and MUC3), all 4 colon **cancer** cell lines expressed mucin message, but the types of mucin mRNA expressed differed. Thus, mucin-like glycoproteins can be synthesized by cell lines derived from non-mucinous colon **cancer**, whether or not they undergo spontaneous differentiation in culture. These cell lines may serve as in vitro models for studying apomucin heterogeneity and control of mucin gene expression.

AN 116:171016 CA  
 TI Mucin synthesis and secretion in relation to spontaneous differentiation of colon cancer cells in vitro  
 AU Niv, Yaron; Byrd, James C.; Ho, Samuel B.; Dahiya, Rajvir; Kim, Young S.  
 CS Gastrointest. Res. Lab., VA Med. Cent., San Francisco, CA, 94121, USA  
 SO Int. J. Cancer (1992), 50(1), 147-52  
 CODEN: IJCNAA; ISSN: 0020-7136  
 DT Journal  
 LA English

L4 ANSWER 22 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 14  
 AB The biochem. compn. of proteoglycans was investigated in human breast tissues of different age either with invasive mammary carcinoma or with benign lesions of the breast. Proteoglycans were extd. from tissues under dissociative conditions (4M guanidine-HCl), isolated by CsCl gradient ultracentrifugation, and purified by gel exclusion and ion exchange chromatog. Glycosaminoglycan side chain compns. of proteoglycans were evaluated by enzymic anal. (**chondroitinases** ABC and AC) and

nitrous acid degradn. Biochem. data indicated that proteoglycans of high d. and mol. size were increased (per wet wt. of tissue) in neoplastic compared to nonneoplastic tissues. Overall proteoglycan content was increased almost 2-fold in tumors. Furthermore, enzymic data revealed a change in the proportions of glycosaminoglycan chains in neoplastic and nonneoplastic tissues. In particular, an increase in chondroitin sulfate (63% vs. 35%, resp.) together with a decrease of dermatan sulfate (12% vs. 45%, resp.) characterized tumors in comparison to mammary tissues

with

benign lesions, while the relative content of heparan sulfate side chains remained similar in both tissues. However, morphometric analyses

revealed

that heparan sulfate content per epithelial cell vol. was in fact decreased in neoplastic tissue. These differences in proteoglycans indicate that there are significant changes in the extracellular matrix and surface properties of cells in breast **cancer** tissue.

AN 114:140763 CA

TI Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues

AU Alini, Mauro; Losa, Gabriele A.

CS Lab. Patol. Cell., Ist. Contonale Patol., Locarno, 6604, Switz.

SO Cancer Res. (1991), 51(5), 1443-47

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

L4 ANSWER 23 OF 41

MEDLINE

DUPLICATE 15

AB The isolation and partial characterization of a novel anticoagulant from the plasma of a patient with metastatic prostate **cancer** is described. The patient had a prolonged activated partial thromboplastin time, prothrombin time and thrombin time which did not correct by mixing with normal plasma. The reptilase time was normal and the prolonged thrombin time was corrected with protamine sulfate suggesting a heparin-like anticoagulant. A glycosaminoglycan anticoagulant (GAC) was isolated from the patient's plasma. The inhibitory activity of the GAC

was

destroyed by treatment with **chondroitinase** ABC. The GAC migrated on agarose gel electrophoresis between keratin sulfate and heparan sulfate. Purified GAC possessed only 2% (W/W) of the antithrombin III cofactor activity of porcine heparin. In assays using purified

fibrinogen,

the GAC was shown to directly inhibit fibrinogen proteolysis by thrombin. It is concluded that this glycosaminoglycan anticoagulant directly inhibits thrombin clotting of fibrinogen and is a new mechanism for abnormal hemostatic assays in **cancer**.

AN 91377716 MEDLINE

DN 91377716 PubMed ID: 1897511

TI A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer.

AU Lieberman H A; Comenzo R; Allen S T; Dilorio J M

CS William B. Castle Hematology Research Laboratory, Department of Medicine, Boston City Hospital, MA 02118.

NC HL 39665 (NHLBI)

SO AMERICAN JOURNAL OF HEMATOLOGY, (1991 Sep) 38 (1) 24-9.

Journal code: 7610369. ISSN: 0361-8609.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199110

ED Entered STN: 19911108  
Last Updated on STN: 19911108  
Entered Medline: 19911023

L4 ANSWER 24 OF 41 CA COPYRIGHT 2002 ACS

AB The presence of a small amt. of diastase-resistant periodic acid Schiff-pos. material was detected in intracytoplasmic microcysts in 2 out of 30 cases of malignant mesothelioma. The material was also stained by Alcian Blue at pH 2.5 and the stain was resistant to diastase, hyaluronidase, **chondroitinase** or sialidase treatment. It was stained by colloid iron or Mucicarmine, but not by high iron diamine or Alcian Blue at pH 1.0. Metachromasia with toluidine blue was

demonstrated

at pH 4.4, but not at pH 2.5. Ultrastructurally, the material appeared to be as electron-dense mesh-like structures. These results suggest that although the presence of such a material is often used as a neg. evidence when one excludes malignant mesothelioma from glandular **cancers** as diagnosis, one should not overestimate its wt.

AN 114:243688 CA

TI Diastase-resistant periodic acid Schiff-positive materials in malignant mesotheliomas

AU Kobuke, Toshihiro; Yonehara, Shuji; Inai, Kouki; Tokuoka, Shoji; Fukuhara,

Toshiyuki; Egawa, Hiromi; Hayashi, Yuzo

CS Sch. Med., Hiroshima Univ., Hiroshima, Japan

SO Byori to Rinsho (1990), 8(6), 801-7

CODEN: BYRIEM; ISSN: 0287-3745

DT Journal

LA Japanese

L4 ANSWER 25 OF 41 MEDLINE DUPLICATE 16

AB Colon **cancer** cells in culture synthesize and secrete mucin glycoproteins, which carry a number of **cancer**-associated antigens. However, the structures and mechanisms of biosynthetic processing are not well understood. Mucins synthesized and secreted by LS174T human colon **cancer** cells were compared to those in LS174T xenografts in athymic mice. Mucins radiolabeled with glucosamine or sulfate were purified by gel filtration and cesium chloride density gradient centrifugation. The mucins were of high molecular weight and

were

resistant to **chondroitinase** ABC, hyaluronidase and HNO<sub>2</sub> treatment. They were, however, susceptible to pronase digestion and mild alkaline treatment. Using radiochemical precursors, the cellular mucin

was

shown to contain fucose, galactose, N-acetylgalactosamine, N-acetylglucosamine, N-acetylneuraminic acid, and sulfate. Oligosaccharides released by beta-elimination had

N-acetylgalactosaminitol

as the reduced amino sugar and also unreduced galactosamine, indicating that there is N-acetyl-galactosamine O-glycosidically attached to protein core and also peripheral N-acetyl-galactosamine not directly linked to protein. DEAE-cellulose chromatography of mucins showed two major peaks with both intracellular and secreted mucins, but xenograft mucins also

had

more acidic components. Sulfate-labeled mucins were shifted to less acidic

peaks by neuraminidase digestion, which indicates that the same mucin molecules are both sialylated and sulfated. We conclude that the intracellular mucins of cultured colon **cancer** cells, those

secreted into the medium, and those in nude mouse xenografts are chemically similar, but differ in sialic acid and sulfate content. This experimental model system, LS174T cells maintained in culture and as nude mouse xenografts, may be useful for further biosynthetic and structural studies of colon **cancer** mucin.

AN 89283549 MEDLINE  
DN 89283549 PubMed ID: 2734549  
TI Comparison of metabolically labeled mucins of LS174T human colon cancer cells in tissue culture and xenograft.  
AU Siddiqui B; Byrd J C; Fearney F J; Kim Y S  
CS Gastrointestinal Research Laboratory, Veterans Administration Medical Center, San Francisco, Calif.  
NC CA47551 (NCI)  
SO TUMOUR BIOLOGY, (1989) 10 (2) 83-94.  
Journal code: 8409922. ISSN: 1010-4283.  
CY Switzerland  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198907  
ED Entered STN: 19900309  
Last Updated on STN: 19970203  
Entered Medline: 19890718

L4 ANSWER 26 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 17  
AB Immunohistochem. localization and distribution of proteoglycans (PG) were obsd. in non-neoplastic and neoplastic tissues. Chondroitin 6-sulfate  
PG,

revealed with antibody 3B3 after **chondroitinase** ABC-treatment, localized in the artery walls, perivascular connective tissue, interstitial element of bone marrow, basement membrane components of neoplastic tissues (adenoid cystic carcinoma, and breast tumor). The 3B3 was also markedly reactive with the connective tissue proliferating from blood vessels and muscle tissues in assocn. with the invasive growth of tumor cells. The interstitial elements, so-called specific stroma within the **cancer** cell nests contained chondroitin 4-sulfate PGs and large PG, whereas the surrounding connective tissue and the preexisting fibrous connective tissue involved in the tumor growth consisted of dermatan sulfate PG with a considerable amt. of chondroitin 4-sulfate PG. Dermatan sulfate PG could be detected by antibody 9A2-staining after chondroitin B-lyase treatment.

AN 113:188983 CA  
TI Immunohistochemical localization of proteoglycans of human non-neoplastic and neoplastic tissues  
AU Takeuchi, Jun; Fukatsu, Toshiaki; Nagasaka, Tetsuro; Nakashima, Nobuo; Ogura, Takeshi; Katoh, Takeshi; Yoshida, Keiichi  
CS Sch. Med., Nagoya Univ., Nagoya, Japan  
SO Ketsugo Soshiki (1989), 21(2), 35-6  
CODEN: KESOD3; ISSN: 0389-7079  
DT Journal  
LA English

L4 ANSWER 27 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 18  
AB The antigenic determinant recognized by monoclonal antibody SPan-1 is greatly elevated in sera of patients with pancreatic **cancer** but not in sera of normal individuals. This study describes the mucin-like characteristics of the SPan-1 antigen isolated from culture medium and xenografts of the human pancreatic **cancer** cell line SW-1990. YPan-1, another pancreatic **cancer** assocd. monoclonal antibody, also reacts with the SPan-1-antigen. The SPan-1/YPan-1 antigens have

densities of 1.4-1.5 g/mL and elute in the void vol. of Sepharose CL-2B columns. They are resistant to degrdn. by **chondroitinase** ABC, nitrous acid, and hyaluronidase but susceptible to protease digestion and reductive .beta.-elimination. All these characteristics suggest that the SPan-1 and YPan-1 determinants are carried on mucinous antigens. Both SPan-1 and YPan-1 immunoreactivities are unaffected by boiling or by alkylation and redn. of the mucins, but they are abolished by mild periodate oxidn. or neuraminidase and are markedly decreased by wheat

germ

agglutinin. Thus, their antigenic determinants are composed principally of carbohydrates with sialic acid, an abs. requirement for reactivity. However, the epitope specificities of SPan-1 and YPan-1 are different since YPan-1 does not compete with SPan-1 for binding to antigen. Moreover, YPan-1 and SPan-1 can be distinguished from several other

sialic

acid-requiring, **cancer** assocd. antibodies such as B72.3, CSLEX-1, DU-PAN-2, OC-125, and 19-9 by either their epitope characteristics or their tissue reactivity patterns.

AN 109:126657 CA

TI Mucin-like antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies SPan-1 and YPan-1

AU Ho, Jenny J. L.; Chung, Yong Suk; Fujimoto, Yasuhisa; Bi, Ning; Ryan, Whitney; Yuan, Shi Zhen; Byrd, James C.; Kim, Young S.

CS Dep. Med., Univ. California, San Francisco, CA, 94121, USA

SO Cancer Res. (1988), 48(14), 3924-31

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

L4 ANSWER 28 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 19

AB The human colon **cancer** cell line Caco-2 displayed in vitro morphol. differentiation which was growth-related. This phenomenon was studied in relation to the cell surface glycosaminoglycans produced by growing (5-day, prior to differentiation) and confluent (9-day, after morphol. and functional differentiation) cultures. Neosynthesized [35S]glycosaminoglycans were purified on DEAE-cellulose; at confluency, they were bound more strongly to the column than the corresponding fractions from the growing cells. Anal. of elution data of heparan sulfate and chondroitin sulfates from growing and confluent cells indicated an increase in chain length of both glycosaminoglycans in morphol. differentiated cells. Heparan sulfate was the main 35S-labeled glycosaminoglycan of the cell surface of both 5- and 9-day cultures. Paper chromatog. of the unsatd. disaccharides obtained by **chondroitinase** digestion showed that chondroitin sulfate chains were primarily 6-sulfated in the 2 studied exts. Heparan sulfate chains were isolated as **chondroitinase**-resistant material and treated with HNO<sub>2</sub>. Anal. of N- and O-sulfate group-related radioactivity showed an increase in the amt. of 35S-label in the form of N-sulfate groups and an increase in the O-35S-sulfation pattern in heparan sulfate from morphol. differentiated cells. Thus, the structural features of both chondroitin sulfates and heparan sulfate were different when the growing cells became morphol. differentiated.

AN 109:71286 CA

TI Biosynthesis of glycosaminoglycans in the human colonic tumor cell line Caco-2: structural changes occurring with the morphological differentiation of the cells

AU Levy, Peggy; Robert, Agnes; Picard, Jacques

CS Lab. Biochim., Fac. Med. St. Antoine, Paris, 75571, Fr.

SO Biol. Cell (1981) (1988), 62(3), 255-64

CODEN: BCELDF; ISSN: 0248-4900

DT Journal  
LA English

L4 ANSWER 29 OF 41 MEDLINE DUPLICATE 20  
AB Immunohistochemical localization of chondroitin sulphate and dermatan sulphate proteoglycans (PGs) was observed in 70 tumour tissues, using monoclonal antibodies 9A-2 and 3B-3 raised against core molecules

obtained

from chondroitin sulphate PG by **chondroitinase** ABC-treatment. They recognize a stub of delta Di-4S and delta Di-6S binding to core protein via a linkage tetrasaccharide, respectively. The antibody 6B6 raised against dermatan sulphate PG obtained from an ovarian fibroma capsule in our laboratory was also used. The interstitial fibrous elements, so-called 'specific stroma' within the **cancer** cell nests contained chondroitin 4-sulphate PG as revealed with 9A-2, whereas the surrounding connective tissue and the preexisting fibrous connective tissue involved in the tumour growth consisted of dermatan sulphate PG with a considerable amount of chondroitin 4-sulphate PG. Chondroitin 6-sulphate PG as revealed with 3B-3 was located in the connective tissue proliferating from blood vessels and muscle tissue in association with

the

invasive growth of tumour cells. Chondroitin 6-sulphate PG was also observed in the basement membrane components of some tumours. In non-epithelial tumours (fibrogenic, chondrogenic, osteogenic and neurogenic tumours), chondroitin 4-sulphate was in fibrous portions. When collagenization and hyalinization progressed, dermatan sulphate PG was observed to increase in quantity.

AN 88163328 MEDLINE  
DN 88163328 PubMed ID: 3348950  
TI Immunohistochemical localization of chondroitin sulphate and dermatan sulphate proteoglycans in tumour tissues.  
AU Fukatsu T; Sobue M; Nagasaka T; Ohiwa N; Fukata S; Nakashima N; Takeuchi J  
CS Division of Pathology, Nagoya University Hospital, Japan.  
SO BRITISH JOURNAL OF CANCER, (1988 Jan) 57 (1) 74-8.  
Journal code: 0370635. ISSN: 0007-0920.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198804  
ED Entered STN: 19900308  
Last Updated on STN: 19900308  
Entered Medline: 19880429

L4 ANSWER 30 OF 41 CA COPYRIGHT 2002 ACS  
AB A reagent contg. monoclonal antibodies to disaccharides I (R10, R20, R30, R40 = sulfate, OH), and treatment of tissue samples with **chondroitinase** and then with monoclonal antibodies to I for histochem. examn. for clin. diagnosis are disclosed. Tissues from patients with stomach **cancer** were fixed, embedded, sectioned, treated for endogenous peroxidase inactivation, treated with **chondroitinase**, treated with 1st antibody (com. PG-.DELTA.Di-OS monoclonal antibody) and then peroxidase-labeled 2nd antibody, and stained. Microscopic properties of samples were compared with those of samples from normal controls.  
AN 109:166874 CA  
TI Monoclonal antibody-containing reagents and their use in clinical diagnosis  
IN Sofue, Mitsuko; Ogura, Taku; Yoshida, Keiichi

PA Seikagaku Kogyo Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 8 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62235565	A2	19871015	JP 1986-78284	19860407
	JP 07113642	B4	19951206		

L4 ANSWER 31 OF 41 CA COPYRIGHT 2002 ACS DUPLICATE 21  
AB Sulfated macromols. synthesized in tumor and mucosa tissues derived from colorectal **cancer** patients were labeled with [35S]sulfate and sepd. into two fractions on DEAE-Sephacel: the slightly acidic peak (peak I) was eluted with 0.2 M NaCl and the highly acidic peak (peak II) was eluted with 0.5 M NaCl. A total of 40 specimens, which included primary colon **cancer**, liver metastases, and normal mucosa obtained at surgery (16 patients), were examd. regarding the amt. of peak I and peak II. The amt. of peak I decreased in the order of normal mucosa > primary tumors > metastases, whereas the amt. of peak II did not change among the tissues. Peak I was mostly resistant to **chondroitinase** ABC and nitrous acid treatment under acidic conditions, whereas combined **chondroitinase**-sensitive materials and nitrous acid-sensitive materials were greater than 80% of the radioactivity in peak II. The major radioactive component of peak I migrated at a position corresponding

to mol. wt. (Mr) > 300,000 by SDS-PAGE and became Mr < 40,000 after alk. borohydride treatment. The major component of peak I was likely to be a sulfated glycoprotein contg. sulfate groups on alk. labile carbohydrate chains. Peak II consisted of a mixt. of heparan sulfate proteoglycans

and chondroitin sulfate proteoglycans. Differential incorporation of [35S]sulfate into peak I among normal mucosa, primary colon carcinoma, and colon carcinoma metastasis was obsd. Therefore, decreased peak I prodn. may be a biochem. change assocd. with colorectal **cancer** progression and metastasis.

AN 107:56734 CA  
TI Differential production of high molecular weight sulfated glycoproteins in

normal colonic mucosa, primary colon carcinoma, and metastases  
AU Yamori, Takao; Kimura, Hitomi; Stewart, Kendal; Ota, David M.; Cleary, Karen R.; Irimura, Tatsuro

CS Tumor Inst., M. D. Anderson Hosp., Houston, TX, 77030, USA

SO Cancer Res. (1987), 47(10), 2741-7

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

L4 ANSWER 32 OF 41 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AB The localization of various kinds of acidic glycosaminoglycan (GAG) and sialic acid contained in the stroma adjacent to intact gastric **cancer** cells and preoperatively irradiated gastric **cancer** cells were histochemically re-analyzed in this study. In addition, the presence of keratanase, **chondroitinase** ABC protease free, heparitinase and heparinase, which all serve to dissimilate GAG, were observed. As tissue stain methods, we employed toluidine blue metachromasia staining (pH 4.1 TBM) as well as alcian blue staining (pH 2.5 AB). And then commercially available GAG-dissimilative enzymes and

neuraminidase were used. The results obtained are as follows; 1) Large amounts of GAGs, mainly hyaluronic acid (HA) and chondroitin sulfate A.C(ChS-A,C), were contained in the stroma adjacent to **cancer** cells; heparan sulfate (Hep-S) and keratan sulfate (KS) were also detected. 2) The stroma adjacent to **cancer** cells degenerated by preoperative irradiation was also found to contain abundant GAGs, which were chiefly composed of HA and ChS-A, C, as seen in the components of non-irradiated **cancer** tissue. Hep-S and KS were seen as well. 3) In many cells producing mucus, sialic acid was contained in a large amount.

AN 1988:223390 BIOSIS  
 DN BA85:112625  
 TI A HISTOCHEMICAL STUDY ON THE GASTRIC CANCER STROMA.  
 AU YAMADA T  
 CS DEP. ANATOMY, TOKYO MED. COLL.  
 SO J TOKYO MED COLL, (1987) 45 (6), 1048-1060.  
 CODEN: TIDZAH. ISSN: 0040-8905.  
 FS BA; OLD  
 LA Japanese

L4 ANSWER 33 OF 41 MEDLINE DUPLICATE 22  
 AB We have examined the adhesion of primary Sertoli cells to a seminiferous tubule basement membrane (STBM) preparation in vitro. The STBM isolation procedure (Watanabe, T.K., L.J. Hansen, N.K. Reddy, Y.S. Kanwar, and J.K. Reddy, 1984, **Cancer Res.**, 44:5361-5368) yields segments of STBM that retain their histotypic form in both three-dimensional tubular geometry and ultrastructural appearance. The STBM sleeves contain two laminae: a thick, inner basal lamina that was formed in vivo between Sertoli cells and peritubular myoid cells; and a thinner, outer basal lamina that was formed between myoid cells and sinusoidal endothelial cells. Characterization by immunofluorescence and SDS PAGE revealed that the isolated STBM retained fibronectin, laminin, and putative type IV collagen among its many components. When the STBM sleeves were gently shaken with an enriched fraction of primary Sertoli cells, the Sertoli cells bound preferentially to the luminal basal lamina at the ends of the STBM sleeves. Few Sertoli cells bound to either the outer basal lamina of the STBM sleeves or to vascular extracellular matrix material which contaminated the STBM preparation. 3T3 cells, in contrast, bound to all surfaces of the STBM sleeves. Pretreatment of the STBM sleeves with proteases, 0.1 M Na metaperiodate, 4 M guanidine HCl, or heating to 80 degrees-90 degrees C inhibited luminal Sertoli cell binding, but binding was not inhibited by **chondroitinase** ABC, heparinase, hyaluronidase, or 4 M NaCl. The luminal Sertoli cell binding occurred in the presence or absence of added soluble laminin, but not fibronectin.

The addition of soluble laminin, but not fibronectin, restored random binding of Sertoli cells to trypsinized STBM sleeves. Our in vitro model system indicates that Sertoli cells recognize differences in two basal laminae produced in vivo on either side of myoid cells.

AN 86304543 MEDLINE  
 DN 86304543 PubMed ID: 3528169  
 TI Sertoli cell binding to isolated testicular basement membrane.  
 AU Enders G C; Henson J H; Millette C F  
 NC HD-06468 (NICHD)  
 HD-15269 (NICHD)  
 T32-HD-07130 (NICHD)  
 SO JOURNAL OF CELL BIOLOGY, (1986 Sep) 103 (3) 1109-19.  
 Journal code: 0375356. ISSN: 0021-9525.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)

LA English  
FS Priority Journals  
EM 198610  
ED Entered STN: 19900321  
Last Updated on STN: 19970203  
Entered Medline: 19861015

L4 ANSWER 34 OF 41 MEDLINE DUPLICATE 23  
AB The murine monoclonal antibody (Mab) designated DF3 has defined a high m.w. antigen detectable in human breast carcinomas and in human milk. DF3 antigen is detectable on apical borders of secretory mammary epithelial cells and in the cytosol of less differentiated malignant cells. DF3 antigen expression has been shown to correlate with the degree of human breast tumor differentiation, and the detection of a cross-reactive species in human milk has suggested that DF3 antigen might be useful as a biochemical marker of differentiated mammary epithelial cells. To further characterize DF3 antigen, we have developed an approach to purify the cross-reactive species by using gel filtration and antibody affinity chromatography. The affinity column-purified DF3 antigen was absorbed by wheat germ agglutinin and peanut agglutinin, but not by concanavalin A or lentil lectin. In contrast, wheat germ agglutinin inhibited MAb DF3 reactivity with the purified antigen, whereas there was little, if any, inhibition when using peanut agglutinin. These findings are thus consistent with the involvement of terminal N-acetyl-D-neuraminic acid and/or N-acetylglucosamine residues in the antigenic site. DF3 antigenicity was also sensitive to neuraminidase, but not chondroitinase ABC, chondroitinase AC, chondroitin-4-sulfatase, or hyaluronidase. Furthermore, DF3 antigen was sensitive to Pronase, subtilisin BPN', and alpha-chymotrypsin. The presence of O-glycosidic linkages between carbohydrate and protein in the DF3 antigenic site was further supported by the presence of NaBH4-sensitive sites. Together, these results suggest that sialyl oligosaccharides present on a peptide backbone are required for maintaining DF3 antigenicity. Similar findings have been demonstrated for DF3 antigen purified from both human milk and breast **cancer** effusions. However, the DF3 antigen in human milk consisted of a single high m.w. species, whereas the tumor-associated antigen consisted of two distinct glycoproteins with m.w. of 330,000 and 450,000. These findings may be relevant to the recent demonstration that distinct high m.w. DF3 antigens are elevated in the circulation of patients with breast carcinoma.

AN 86009667 MEDLINE  
DN 86009667 PubMed ID: 4045199  
TI Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas.  
AU Sekine H; Ohno T; Kufe D W  
NC CA38869-01A1 (NCI)  
SO JOURNAL OF IMMUNOLOGY, (1985 Nov) 135 (5) 3610-5.  
Journal code: 2985117R. ISSN: 0022-1767.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 198511  
ED Entered STN: 19900321  
Last Updated on STN: 19970203  
Entered Medline: 19851121

L4 ANSWER 35 OF 41 MEDLINE DUPLICATE 24  
AB Sulfation of glycosaminoglycans (GAGs) secreted by baby hamster kidney

(BHK) cells and the polyoma virus-transformants (PY-BHK) was investigated.

It has been reported that chondroitin sulfate (CS) of cell membranes from PY-BHK cells is undersulfated compared to that from BHK cells ( **Cancer Res.** 43, 2712-2717, 1983). In the first series of experiments of the present study, cells were incubated with [3H]glucosamine and [35S]sulfate, and GAGs isolated from the culture medium were examined. GAG composition was comparable between the BHK and PY-BHK cultures. Disaccharide analysis of the **chondroitinase** ACII digests of the hyaluronate lyase-resistant materials showed a high proportion (68% for BHK and 47% for PY-BHK) of delta Di-OS, with delta Di-4S (32% for BHK and 53% for PY-BHK) as the major sulfated disaccharide on the basis of 3H-radioactivities. The beta-D-xyloside treatment did not alter the degree of undersulfation of the CS of either culture. In the second series of experiments, disaccharide analysis of the **chondroitinase** ABC digests of unlabeled GAGs demonstrated similar disaccharide composition for the two cell types. The BHK and PY-BHK preparations showed 28 and 17% (mol percent) of delta Di-OS, 58 and 72%

of delta Di-4S, and 14 and 11% of delta Di-6S, respectively. These results indicate a considerable degree of undersulfation of secretory CS from

both cells, and a slightly higher degree, if any, of under-sulfation of secretory CS from BHK cells if compared between the two cell types, which is in contrast to the results reported for membrane CS.

AN 86085767 MEDLINE  
DN 86085767 PubMed ID: 3001040  
TI Sulfation of chondroitin sulfate secreted by baby hamster kidney cells  
and

their polyoma virus-transformed counterparts.

AU Sugahara K; Fukui S; Yamashina I  
SO JOURNAL OF BIOCHEMISTRY, (1985 Oct) 98 (4) 875-85.  
Journal code: 0376600. ISSN: 0021-924X.

CY Japan  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198602  
ED Entered STN: 19900321  
Last Updated on STN: 19980206  
Entered Medline: 19860220

L4 ANSWER 36 OF 41 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AB The clinical and operative findings in 26 patients with pancreatic carcinoma were studied according to the General Rules for Surgical and Pathological Studies on **Cancer** of Pancreas edited by the Japanese Pancreatic Society. By staining with Alcian blue (AB) plus Toluidine blue (TB) and treatment with several acid mucopolysaccharides (AMPS) digesting enzymes, the histochemical examination of mucosubstances was made using the fixed and sectioned materials of the pancreatic carcinoma. Several stainings were performed to the 15 cases of duct cell carcinoma of resected pancreatic carcinomas with AB staining at pH 1.0

and pH 2.5, TB staining at pH 2.5 and pH 4.1 and PAS staining. Several enzymic

digesting methods were performed on 15 with duct cell carcinoma of resected pancreatic carcinomas with Testicular Hyaluronidase, Streptomyces

Hyaluronidase, **Chondroitinase** ABC, **Chondroitinase** AC-II and Neuraminidase respectively. The following results were obtained.

2/3 of resected patients had a tumor exceeding 4.1 cm. In over 70%, there was infiltration into the capsule of the pancreas and to the portal vein system and the majority (92%) were stage III to IV. In the histopathologic

classification, 23 of resected 26 were cases of duct cell carcinoma and 18

were tubular adenocarcinoma. Histopathologically, many cases were IFN .gamma., ly, s and ew positive ones. Cellular and structural atypism were also strong. Lymph node metastasis was microscopically evident in about 80% of cases. With AB staining, the stainability in the well differentiated cases of pancreatic carcinoma was stronger in the interstitial portion than in the parenchymal portion and this tendency

was

stronger in the poorly differentiated than in the well differentiated cases. With TB staining, the stainability in the well differentiated

cases

was similar both in the parenchymal and interstitial portion. The tendency

was relatively strong in the poorly differentiated compared with the well differentiated cases. In the enzymic digesting test, AMPS were seen to

be

moderate in the interstitial portion and sialic acid was seen slightly both in the parenchymal and interstitial portion of the well differentiated cases. On the other hand, AMPS were seen to be moderate in the parenchymal portion and abundantly in the interstitial one and sialic acid was seen moderately in the interstitial portion and was not seen in the parenchymal portion of the poorly differentiated cases. Most of resected pancreatic carcinomas were highly infiltrative and advanced.

With

histochemical analysis, AMPS were seen more frequently in the

interstitial

portion of the poorly differentiated than in the well differentiated

cases

and sialic acid was also seen in the interstitial portion of the poorly differentiated cases. These results suggest that AMPS and sialic acid are related to the development and growth-promoting effect of pancreatic carcinoma.

AN 1986:202690 BIOSIS

DN BA81:93990

TI CLINICAL AND HISTOCHEMICAL STUDIES ON RESECTED PANCREATIC CARCINOMA WITH REFERENCE TO MUCOSUBSTANCES IN THE TUMOR TISSUES.

AU YAMAMOTO S

CS FIRST DEPARTMENT OF SURGERY, OSAKA CITY UNIVERSITY MEDICAL SCHOOL.

SO J OSAKA CITY MED CENT, (1985 (RECD 1986)) 34 (2), 169-202.

CODEN: OIGZDE. ISSN: 0386-4103.

FS BA; OLD

LA Japanese

L4 ANSWER 37 OF 41 MEDLINE DUPLICATE 25

AB Seventy five prostatic specimens from **cancer**, BPH and normal controls were studied by light microscopic histochemical methods for the demonstration of complex carbohydrates and some proteins: 1) alcian blue (AB) (pH 1.0), 2) alcian blue (AB) (pH 2.5), 3) Periodic Acid-Schiff (PAS), 4) peroxidase labelled-Ricinus communis

agglutinin-diaminobenzidine

(PO-RCA-DAB), 5) Concanavalin A-peroxidase-diaminobenzidine

(ConA-PO-DAB),

6) ConA-PO-DAB-periodic acid-m-aminophenol Fast black salt K

(ConA-PO-DAB-PA-AP-FBK). For identifying individual acidic and neutral carbohydrates, following procedures of enzyme digestion were performed

upon some tissue sections prior to the above histochemical staining: a) sialidase (prior to staining with AB at pH 2.5), b) streptomyces hyaluronidase (prior to staining with AB at pH 2.5), c) testicular hyaluronidase (prior to staining with AB at pH 1.0 or pH 2.5), d) **chondroitinase** ABC (prior to staining with AB at pH 1.0 or pH 2.5), e) **chondroitinase** AC (prior to staining with AB at pH 1.0 or pH 2.5), f) alpha-amylase (prior to staining with PAS). In addition, the tissue specimens from prostatic **cancer** were stained immunohistochemically for demonstration of prostatic acid phosphatase (PAP) and the serum PAP levels were also measured by radioimmunoassay.

The

histochemical differences in the prostatic tissue among normal control, BPH and **cancer** as follows. In the tissue of prostatic **cancer**, chondroitin sulfate A, C and hyaluronic acid were present in the interstitium. Chondroitin sulfate, hyaluronic acid and sialic acid were present in the cytoplasm of **cancer** cells. In the tissue of BPH chondroitin sulfate B and hyaluronic acid was present in the interstitium and hyaluronic acid was present in the cytoplasm of epithelial cells. In the epithelial basement membrane of the tissue from BPH, chondroitin B and hyaluronic acid were present. 1,2-Glycol groups of neutral complex carbohydrates in the interstitium of prostatic **cancer** were shown to exist in smaller amounts than in that of BPH. In the cytoplasm of **cancer** cells the intensity of both PO-RCA-DAB and ConA-PO-DAB staining could be divided into three groups: strong, moderate and weak. In the prostatic **cancer** there was a good correlation between the intensity of PO-RCA-DAB staining and tumor grade, and intensity of ConA-PO-DAB staining was correlated well with serum PAP level. The cytoplasm of **cancer** cells showed a positive reaction to PAP immunostaining and no appreciable difference was observed according to tumor grade. (ABSTRACT TRUNCATED AT 400 WORDS)

AN 85195797 MEDLINE  
 DN 85195797 PubMed ID: 2581429  
 TI The histochemistry of complex carbohydrates in the prostatic tumor.  
 AU Sugiyama T  
 SO HINYOKIKA KIYO. ACTA UROLOGICA JAPONICA, (1985 Jan) 31 (1) 49-69.  
 Journal code: 0421145. ISSN: 0018-1994.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA Japanese  
 FS Priority Journals  
 EM 198506  
 ED Entered STN: 19900320  
 Last Updated on STN: 19970203  
 Entered Medline: 19850619

L4 ANSWER 38 OF 41 MEDLINE  
 AB A case of breast **cancer** with cartilage-like structure is presented. The stroma, resembling cartilagenous martrix upon hematoxylin and eosin staining, showed metachromasia upon toluidine blue staining. However, predigestion with hyaluronidase or **chondroitinase** ABC revealed no change in toluidine blue (pH 2.5) staining, suggesting the absence of not only hyaluronic acid but also of chondroitin sulfate in this structure. It is therefore reasonable to conclude that the cartilage-like structure found in this case may have been derived from epithelial mucinous substances, similar to those observed in common mucinous carcinoma of the breast.

AN 84115271 MEDLINE  
 DN 84115271 PubMed ID: 6663716  
 TI Case of breast cancer with cartilage-like structure.  
 AU Samoto T; Kobayashi S; Masaoka A; Nakamura T; Miura K

SO GAN NO RINSHO. JAPANESE JOURNAL OF CANCER CLINICS, (1983 Nov) 29 (14)  
1682-5.

Journal code: 1257753. ISSN: 0021-4949.

CY Japan

DT Journal; Article; (JOURNAL ARTICLE)

LA Japanese

FS Priority Journals

EM 198403

ED Entered STN: 19900319

Last Updated on STN: 19900319

Entered Medline: 19840306

L4 ANSWER 39 OF 41 MEDLINE

DUPLICATE 26

AB Heparan sulfate fractions were isolated from three normal human livers  
and

three **cancerous** human liver tissues, and their polyanionic properties were examined using electrophoresis, sequential partition fractionation, and chemical analyses. More than 60% of total glycosaminoglycans from normal human liver and about 30% from **cancerous** liver tissue were found to be heparan sulfate from their resistance to exhaustive digestion with **chondroitinase** ABC and their susceptibility to nitrous acid treatment. The heparan sulfate isolated from **cancerous** liver tissue afforded a lower sulfate/uronic acid molar ratio (0.58 to 0.65) than did normal human

liver

heparan sulfate (0.76 to 0.80). Also, the former showed lower electrophoretic mobility in 0.1 M HCl and a different partition fractionation profile in comparison with the latter. These differences in charge density of the macromolecule were not detected on the chondroitin sulfate and/or dermatan sulfate fractions isolated from normal human

liver

and **cancerous** liver tissue.

AN 81088165 MEDLINE

DN 81088165 PubMed ID: 6449994

TI Changes in charge density of heparan sulfate isolated from cancerous human

liver tissue.

AU Nakamura N; Kojima J

SO CANCER RESEARCH, (1981 Jan) 41 (1) 278-83.

Journal code: 2984705R. ISSN: 0008-5472.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198103

ED Entered STN: 19900316

Last Updated on STN: 19900316

Entered Medline: 19810317

L4 ANSWER 40 OF 41 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB The cell surface glycoconjugates of various rat ascites hepatoma cell lines with different degrees of adhesiveness were compared by binding assays using 125I-labeled lectins. The effects of neuraminidase, TPCK-trypsin and **chondroitinase** ABC treatment on the number of lectin receptor sites were studied. The TPCK-trypsin treatment caused a marked decrease in the number of peanut agglutinin receptor sites on the island-forming and mixed cell types. The decrease of wheat germ agglutinin

receptor sites and the increase of castor bean agglutinin receptor sites after neuraminidase treatment were larger on the free cell type. It is

possible that .alpha.-sialyl-.beta.-D-galactosyl residues are abundant on the cell surface of this type and that its low cell adhesiveness may be due to a electrostatic repulsion of negative charges of the sialic acid. [The role of cell adhesion in **cancer** is discussed.]

AN 1982:282614 BIOSIS

DN BA74:55094

TI DIFFERENCE OF LECTIN RECEPTORS BETWEEN THE FREE CELL TYPE AND ISLAND FORMING CELL TYPE OF RAT ASCITES HEPATOMA CELLS.

AU KITAGAKI H; MATSUMOTO I; SENO N; NAGASE S

CS DEP. CHEM., FAC. SCI., OCHANOMIZU UNIV., BUNKYO-KU, TOKYO 112, JAPAN.

SO NAT SCI REP OCHANOMIZU UNIV, (1981 (RECD 1982)) 32 (2), 115-126.

CODEN: NASOA5. ISSN: 0029-8190.

FS BA; OLD

LA English

L4 ANSWER 41 OF 41 CA COPYRIGHT 2002 ACS

DUPLICATE 27

AB Glycosaminoglycans were characterized from a normal human breast cell line

(HBL-100) and two different cell lines from human breast carcinoma (MDA-MB-231 and MCF-7). The glycosaminoglycans were labeled by exposure of cell cultures to glucosamine-3H and sulfate-35S and then isolated from both spent media and cells by pronase digestion and cetylpyridinium chloride fractionation. They were further characterized by hexosamine compn., controlled-pore glass exclusion chromatog., reactivity with specific enzymes (hyaluronidase, **chondroitinase**, heparitinase, and heparinase), nitrous acid degrdn., and DEAE-Sephadex chromatog. The results indicated that the HBL-100 line synthesized mainly hyaluronic acid, most of which was secreted into the medium. Chondroitin sulfate

and

heparan sulfate were the predominant glycosaminoglycans synthesized by

the

**cancer** lines. Both were found mainly in the spent medium, but the hyaluronic acid synthesized by the MDA-MB-231 line remained cell assocd. The cell-assocd. heparan sulfate had a mol. wt. in excess of 13,000 and may contain linkages susceptible to testicular hyaluronidase. The MCF-7 cells produced significantly lower amts. of glycosaminoglycans than did the other two lines.

AN 90:135939 CA

TI Glycosaminoglycans of normal and malignant cultured human mammary cells

AU Chandrasekaran, E. V.; Davidson, Eugene A.

CS Spec. Cancer Res. Cent., Pennsylvania State Univ., Hershey, Pa., USA

SO Cancer Res. (1979), 39(3), 870-80

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English